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INTRODUCTION
Subarachnoid hemorrhage (SAH) produced by a ruptured
intracranial aneurysm (IA) affects about 10/100,000 persons
annually (1). And, although significant advances have been
made in the treatment of aneurismal SAH and vasospasm (2),
SAH is currently a significant healthcare problem; moreover,
delayed ischemic neurological deterioration (DIND) due to
vasospasm remains the greatest cause of morbidity and mor-
tality after SAH (3). The catastrophic consequences of a rup-
tured IA and the high frequency of IA in the general popu-
lation demand intensive efforts to define a multifactorial risk
model for the identification of those at risk of developing an
IA, of rupture of an existing IA, and those at risk of DIND
after SAH. 
It is known that smoking, alcohol consumption, and hyper-
tension are common risk factors of aneurismal SAH (4). In
addition, to these environmental risk factors, genetic factors
also play an important role in the pathogenesis of SAH and
IAs, as the first degree relatives of patients with the disorder
have up to a seven times greater risk than the general population
(5), and about 10% of patients with an aneurismal SAH have
first or second degree relatives with SAH or unruptured IAs
(6). As this familial predisposition is the strongest risk factor
for the development of IA (4), the detection of genetic risk
factors could provide further diagnostic capabilities. 
Disruption of the extracellular matrix is likely to be a factor
in the pathophysiology of IA, because IAs are associated with
heritable connective tissue and extracellular matrix disorders
(7). In this context, the genes involved in maintaining the inte-
grity of the extracellular matrix have been proposed to be the
most likely candidates for predisposing an individual to IA
development. However, variations in these genes only explain
a small proportion of the genetic factors involved in IA (8).
Therefore, further studies are needed to identify candidate genes
and to help unravel the pathophysiology of this disorder.
Given mounting evidence that genetic factors play a role
in IA formation and rupture (1, 9-11), the endothelial nitric
oxide synthase gene (eNOS) is being considered as a potential
candidate gene that contributes to IA formation and vasospasm
after SAH, based on its normal physiologic effects on the cere-
bral arteries. In the arterial endothelium of animals and hu-
mans, the synthesis of nitric oxide (NO) from L-arginine is
catalyzed by the enzyme eNOS (12), and the continuously gen-
erated NO serves to maintain basal vascular tone and cerebral
blood flow (CBF) (13-15). In addition, when one considers
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Endothelial Nitric Oxide Gene T-786C Polymorphism and 
Subarachnoid Hemorrhage in Korean Population
We aimed to elucidate whether the eNOS T-786C mutant allele is implicated in sub-
arachnoid hemorrhage (SAH) susceptibility or vasospasm after SAH, and whether
the mutant allele is differentially expressed in those with small and large ruptured
aneurysms in Korean population. 136 consecutive patients diagnosed with aneuris-
mal SAH and 113 controls were recruited. Polymerase chain reaction and direct
sequencing of both strands were performed to determine genotypes with respect
to the eNOS T-786C mutation. No significant difference was found between cases
and controls with respect to the distributions of the two eNOS T-786C single nucleo-
tide polymorphism (SNP) genotypes. No significant differences in the distributions
of the eNOS T-786C SNP genotypes were found with regard to the sizes of ruptured
aneurysms or the occurrence of vasospasm after SAH. Multiple logistic regression
analysis after controlling for age and sex showed the eNOS T-786C SNP T/C geno-
type was independently associated with an unfavorable outcome (GOS grade 3-5)
of SAH (Exp ( )=4.27, 95% CI 1.131-16.108, p=0.032). In conclusion, the eNOS
T-786C mutation was not found to be associated with either a susceptibility to SAH
or vasospasm after SAH, or with aneurysm size in Korean population. The eNOS T-
786C SNP T/C genotype could be used as a prognostic marker in individuals with
SAH.
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that the preferential location of IAs is at the bifurcation of the
conductive cerebral arteries in the subarachnoid space (16), it
can be hypothesized that hemodynamic change in CBF in-
duced by defective eNOS metabolism may affect the cerebral
arterial walls lacking or with disrupted internal elastic lam-
ina, and that this facilitates aneurysm formation (16, 17). 
In the present study, the authors aimed to elucidate both
whether the eNOS T-786C mutant allele is implicated in sus-
ceptibility to SAH, and DIND after SAH, and additionally,
to determine whether this mutant allele is differentially ex-
pressed in those with a small or large ruptured aneurysm.
MATERIALS AND METHODS
Subjects
A total of 249 human subjects were enrolled in this pros-
pective case-control study. Of 136 consecutive patients (cases)
diagnosed with aneurismal SAH based on clinical and radio-
logical findings (including cerebral angiography in all cases), 3
were excluded from analysis because of a previous history of
cerebral infarction or myocardial ischemia. During same peri-
od, 113 controls were recruited from among out-patient clinic
patients with various clinical diagnoses. The control inclusion
criteria were as follows; no cerebral vascular abnormality, in-
cluding aneurysm or thrombosis on CT or MR angiography,
no history of a vascular headache or myocardial ischemia, and
no definite brain lesion on MR imaging. Demographic and
medical history and peripheral blood specimen were obtained
from all participants. The maximal diameters of ruptured
aneurysms were measured by neuroradiologists and the pa-
tients were divided by size into 3 groups in-line with the
findings of aneurysm natural history studies (18, 19), i.e.,
small (≤5 mm), medium (6 to 9 mm), and large (≥10 mm).
SAH severity on admission was classified based on CT scan
findings according to the grading system described by Fisher
(Fisher grades 1 to 4) (20). Clinical SAH severity on admis-
sion was scored using the Glasgow Coma Scale (GCS) (21).
The outcomes of patients with SAH were classified accord-
ing to the Glasgow Outcome Scale (GOS) (22); favorable
outcome group (GOS 1), good recovery; GOS 2, moderate
disability; and an unfavorable outcome group GOS 3, severe
disability; GOS 4, persistent vegetative state; GOS 5, death.
The study protocol was approved by our institutional review
board and all subjects enrolled in the study gave informed
consent.
Genetic analysis
Genomic DNA was extracted from peripheral blood lym-
phocytes using a standard protocol. Polymerase chain reaction
(PCR) primers for eNOS T-7896C SNP were designed based
on GenBank sequences (accession number: NM_000603);
5′ -GCA TGC ACT CTG GCC TGA AGT-3′ (forward) and
5′ -CAG GAA GCT GCC TTC CAG TGC-3′ (reverse). PCR
assays were carried out using 1.25 U of AmpliTaq polymerase
Gold (Applied Biosystem, NJ, U.S.A.), 100 ng genomic
DNA, 2.0 mM of MgCl2, and 10  M of primer. Amplifica-
tion conditions were as follows: an initial denaturing cycle at
95℃for 7 min, followed by 35 amplification cycles (denatura-
tion at 94℃ for 30 sec, annealing at 61℃ for 45 sec, and ex-
tension at 72℃for 1 min), and a final extension step of 72℃
for 5 min. PCR products were electrophoresed in a 1.2% aga-
rose gel, and the amplified genomic DNA fragments were
extracted from the gel and purified using a QIAquick
� gel
extraction kit (Quiagen, Hilden, Germany) according to the
manufacturer’s instructions. Direct sequencing of both strands
was performed using BigDye terminator kits (PE Biosystems,
CA, U.S.A.) to determine individual genotypes. 
Data analysis
When the clinical characteristics of the study participants
were considered, hypertension was defined as blood pressures
>140/95 mmHg, and diabetes mellitus as a fasting blood
glucose level of >126 mg/dL or a random blood glucose con-
centration of >200 mg/dL. 
Continuous variables were compared using 2-tailed unpaired
t-tests. Categorical variables were compared by 
2 analysis
with Fisher’s exact test. Multiple logistic regression analysis
with forward stepwise selection was performed to identify
predictors of SAH occurrence, ruptured aneurysm size, SAH
outcome, and the occurrence of DIND after SAH. Data were
analyzed with SPSS (release 11.5; SPSS, Chicago, IL, U.S.A.)
and differences were considered significant for p values of ≤
0.05. Conformance with the Hardy-Weinberg equilibrium
was tested by comparing the observed and expected genotype
frequencies of the controls using the 
2 test.
RESULTS
Compared with controls, SAH cases were significantly
younger with a preponderance of non-diabetics and smokers
(Table 1). The SAH cases at admission had a mean GCS score
of 12.9. More than 90% of patients presented with Fisher
grade 3 or more, and the mean diameter of ruptured aneu-
rysms was 6.64±2.74 mm. DIND after SAH occurred in
17 patients (12.8%) and more than 80% patients had a favor-
able outcome (GOS grade 1 or 2) (Table 2). 
Among the controls, the frequency of wild type homozy-
gotes (T/T) was 88.5% and of mutant heterozygotes (T/C),
11.5%. No patient or control harbored the mutant C/C ho-
mozygote (Table 1). The frequencies of the eNOS T-786C SNP
genotypes concurred with the Hardy-Weinberg equilibrium
(p=0.516). No significant difference was observed between
cases and controls in the distributions of the eNOS T-786C924 M.-K. Song, M.-K. Kim, T.-S. Kim, et al.
single nucleotide polymorphism (SNP) genotypes (Table 1).
With regard to ruptured aneurysm size and the occurrence of
DIND after SAH, no significant differences were found in
the distributions of the eNOS T-786C SNP genotypes (Table
3). The mean (±SD) ruptured aneurysm diameter of wild-
type homozygotes (T/T; 6.75±2.85 mm) was similar to that
of mutant heterozygotes (T/C; 6.19±2.23 mm) (p=0.29, t-
test).
Multiple logistic regression analysis after controlling for
age and sex showed the eNOS T-786C SNP T/C genotype
was independently associated with unfavorable outcome of
SAH (GOS grade 3-5) (Exp ( )=4.27, 95% CI 1.131-16.108,
p=0.032).
DISCUSSION
Much attention has been focused on the contribution made
by eNOS SNPs to the development and progression of vari-
ous systemic vascular diseases (23-26), because of the role
played by NO in the regulations of vascular tone and hemo-
dynamic changes. With regard to the cardiovascular system,
it has been reported that high numbers of CA repeats in intron
13 and the G894T SNP in exon 7 of the eNOS gene are asso-
ciated with the risk of coronary artery disease (24, 27), and
that the eNOS T-786C mutation is strongly associated with
a history of coronary spasm (23). Of eNOS polymorphisms
that have been linked with coronary artery disease, the eNOS
T-786C mutation is the only one of which functional role has
been elucidated. According to the luciferase reporter gene
assays performed by Nakayama et al. (23), this mutation re-
duces eNOS promoter activity and finally causes a reduction
in NO levels. Therefore, an association between the eNOS gene
variants and coronary artery disease suggests that the eNOS
gene could be associated with aneurismal SAH, in which uni-
que changes in cerebral NO levels have been reported imme-
diately after SAH (28).
Despite the potential link between the eNOS gene and
aneurismal SAH, no definite evidence confirming such an
association has been found. The eNOS T-786C SNP is one of
the most frequently investigated mutations because it is locat-
ed in the eNOS promoter region as thus potentially affects
eNOS expression. In a prospective study involving 141 par-
ticipants (29), it was suggested that the eNOS T-786C mutant
allele does not predict susceptibility to SAH or intracranial
aneurysm rupture but rather predicts susceptibility to post-
SAH vasospasm. However, in the present study, the authors
failed to find any relationship between eNOS T-786C SNP
and the susceptibility to SAH or to DIND after SAH as did
previous studies (29-31). Given the available evidence and
the results of the present study, it is evident that the eNOS
T-786C SNP is not a major risk factor for IA formation or
SAH. However, whether the eNOS T-786C SNP contributes
to vasospasm after SAH remains to be determined because
the sample sizes of the vasospasm groups subjected to analy-
sis in the studies above were too small to determine the con-
tribution made by this SNP to vasospasm after SAH. To date,
a large blood burden is the only consistently demonstrated
risk factor predicting cerebral vasospasm after SAH (32). 
According to the stepwise multiple logistic regression
analysis performed in the present study, the presence of the
eNOS T-786C SNP T/C genotype should be considered as
significant risk factors of outcome in cases of SAH. Interest-
ingly, the odds ratio for an unfavorable outcome (GOS grade
3-5) after SAH for individuals with the eNOS T-786C SNP
T/C genotype was 4.27 (95% CI 1.13-16.11, p=0.032). This
result suggests that the eNOS -786C allele causing a reduction
Except for GSC score (mean±SD), all results expressed as No. (% of
total cases). GSC score, glasgow coma scale score; SAH, subarach-
noid hemorrhage; GOS, glasgow outcome scale.
GCS score at admission 12.9±2.40






Anterior circulation 96 (72.2)
Posterior circulation 35 (26.3)
Both 2 (1.5)




Small (≤5 mm) 58 (43.6)
Medium (6-9 mm) 52 (39.1)
Large (≥10 mm) 23 (17.3)
Symptomatic vasospasm 17 (12.8)
GOS grades
Good recovery 100 (75.2)
Moderate disability 10 (7.5)
Severe disability 19 (14.3)
Vegetate state 0 (0)
Death 4 (3.0)
Table 2. Clinical characteristics of SAH patients (n=133)
Except for age (mean±SD), all results expressed as No. (% of total con-
trols or cases).
*One case was excluded from analysis because of failed PCR.
Controls (n=113) Cases (n=133) p value
Mean age (yr) 61.8±10.5 53.7±11.3 <0.001
Female sex 61 (54.0%) 78 (58.6%) 0.54
History of:
Hypertension 35 (31.5%) 57 (42.9%) 0.09
Diabetes mellitus 17 (15.2%) 8 (6.0%) 0.02
Smoking 6 (5.4%) 44 (33.1%) <0.001
eNOS T-786C genotype* 0.12
T/T 100 (88.5%) 106 (80.3)
T/C 13 (11.5%) 26 (19.7%)
C/C 0 (0%) 0 (0%)
Table 1. Comparison of SAH cases with non-SAH controlseNOS and Subarachnoid Hemorrhage 925
of NO level should be associated with an unfavorable outcome
of SAH. However, the exact explanation for the unfavorable
outcome of SAH in patients presenting the eNOS -786C allele
is out of the scope of the present study. Nevertheless, if the
result is confirmed by a larger scale study, the eNOS T-786C
SNP T/C genotype could be used as a prognostic marker in
individuals with SAH. 
Another controversy concerning aneurysms and the eNOS
gene involves the critical size of aneurysm beyond which rup-
ture risk increases appreciably. In the International Study of
Unruptured IAs (ISUIA) (19), the rupture rate of aneurysms
of ≥10 mm was approximately 20 times that of aneurysms
<10 mm among patients without a prior SAH. This result
suggests that aneurysm size at the time of diagnosis is an inde-
pendent predictor of rupture risk. However, the fact that the
vast majority of ruptured aneurysms are <10 mm in diameter
at the time of diagnosis and treatment (33, 34) reinforces the
notion that aneurysm size should not be used as the sole cri-
terion for treatment decision-making. Explanations for this
apparent discrepancy include the possibility that there are
two distinct subpopulations of IAs; one that develops rapidly
and ruptures when <10 mm in diameter and another that
enlarges slowly and ruptures when >10 mm in diameter. Re-
cently, Khurana et al. (30) suggested that among Caucasian
patients with known IAs that the eNOS T-786C genotype
influence aneurismal size at rupture. They found that the
mean (±SD) ruptured aneurysm diameter for all heterozy-
gotes (T/C; 8.5±5.2 mm) was significantly greater than that
for the C/C (6.0±2.3 mm) or T/T (4.7±1.8 mm) homozy-
gotes (p=0.04). If this finding is reproduced by larger scale
study, genotypes could be used to predict the risk of rupture
in individuals presenting with unruptured IAs. However,
their suggestion is also not free of criticism due to the relative-
ly small size studied (n=52). In addition, according to their
suggestion, it should be stated that both the mutant homozy-
gote (C/C) and the wild type homozygote (T/T) influence
aneurysm development, which is difficult to rationalize. In
the present study of 133 individuals with SAH, no signifi-
cant differences in the distribution of the eNOS T-786C geno-
types were found among the 3 groups defined on the basis
of aneurysm size (Table 3). This negative finding is entirely
consistent with the result of a recent larger scale multicenter
study (n=527) which was performed in East-Asian population
that presented with SAH (31). Considering that the distribu-
tions of the eNOS T-786C genotypes in normal controls are
quite different in these populations (Table 4), discrepancies
between Caucasians and East-Asians in terms of eNOS T-786C
genotype distributions and their relations with aneurysm size
may be attributed to ethnic differences. However, the exact
explanation of the ethnic difference remains to be clear. 
Taken together, the eNOS T-786C mutation was not found
to be associated with either a susceptibility to SAH, or with
aneurysm size in Korean population. And the eNOS T-786C
SNP T/C genotype could be used as a prognostic marker in
individuals with SAH.
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